Speaking of Access: Pricing for Uncertain Indications
Andrew Gould asks our US payer panel for their expert perspectives surrounding pricing for uncertain future indications.
Focusing on TAZVERIK, the panel discuss management expectations, and also disclose whether the expectations of likelihood for approval is ever conferred with them directly.
SUBSCRIBE: